In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, Cytokinetics Inc (NASDAQ: CYTK) closed at $51.51 down -1.44% from its previous closing price of $52.26. In other words, the price has decreased by -$1.44 from its previous closing price. On the day, 0.62 million shares were traded. CYTK stock price reached its highest trading level at $52.24 during the session, while it also had its lowest trading level at $51.19.
Ratios:
For a deeper understanding of Cytokinetics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.39 and its Current Ratio is at 10.39. In the meantime, Its Debt-to-Equity ratio is 7.28 whereas as Long-Term Debt/Eq ratio is at 7.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Goldman on August 13, 2024, Downgraded its rating to Neutral and sets its target price to $60 from $85 previously.
On January 24, 2024, UBS Downgraded its rating to Neutral which previously was Buy and also upped its target price recommendation from $61 to $92.
Morgan Stanley Downgraded its Overweight to Equal-Weight on January 05, 2024, whereas the target price for the stock was revised from $60 to $90.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Oct 29 ’24 when FADY MALIK bought 7,300 shares for $51.91 per share.
WENDELL WIERENGA bought 4,452 shares of CYTK for $232,617 on Oct 28 ’24. On Oct 15 ’24, another insider, Malik Fady Ibraham, who serves as the EVP Research & Development of the company, sold 7,300 shares for $54.19 each. As a result, the insider received 395,554 and left with 116,920 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CYTK now has a Market Capitalization of 6148902912 and an Enterprise Value of 5794045952. For the stock, the TTM Price-to-Sale (P/S) ratio is 1936.32 while its Price-to-Book (P/B) ratio in mrq is 55.77. Its current Enterprise Value per Revenue stands at 1848.77 whereas that against EBITDA is -11.749.
Stock Price History:
Over the past 52 weeks, CYTK has reached a high of $110.25, while it has fallen to a 52-week low of $30.68. The 50-Day Moving Average of the stock is -5.67%, while the 200-Day Moving Average is calculated to be -16.83%.
Shares Statistics:
For the past three months, CYTK has traded an average of 1.20M shares per day and 900520 over the past ten days. A total of 117.66M shares are outstanding, with a floating share count of 113.75M. Insiders hold about 3.33% of the company’s shares, while institutions hold 113.82% stake in the company. Shares short for CYTK as of 1728950400 were 15537953 with a Short Ratio of 12.98, compared to 1726185600 on 17844332. Therefore, it implies a Short% of Shares Outstanding of 15537953 and a Short% of Float of 20.18.
